Agenus shares soar after cancer therapy deal with Gilead


Dec 20 () - Shares of Agenus Inc surged as much as 70 percent on Thursday after the company said it would develop and market up to five of its immuno-oncology therapies in partnership with Gilead Sciences Inc.

Agenus will get an upfront cash payment of $120 million and a $30 million equity investment, and will also be eligible to receive about $1.7 billion in potential fees and milestones, the companies said in a statement.

Gilead will get worldwide exclusive rights to Agenus' AGEN1423; an option to license two other programs, AGEN1223 and AGEN2373, and the right of first negotiation for two additional, undisclosed preclinical programs.

The deal provides Agenus with sufficient capital to develop its wholly owned cancer drug assets, William Blair analyst Matt Phipps said.

The announcement comes a day after Swiss biotechnology company Molecular Partners signed a deal with Amgen Inc to work together in cancer immunotherapy.

Agenus' shares pared some gains and were trading up 57 percent at $3.16 in trading before the bell.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics

World Markets


Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at and via Reuters TV.

Learn More